In support of this, BRD0705, a GSK-3α-selective inhibitor, induced myeloid differentiation and impaired colony formation in AML cells without affecting normal hematopoietic cells and β-catenin stability [63]. Here, GSK3A is linked to acute myeloid leukemia.